Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Yondelis in advanced prostate cancer
NCT00147212Phase 2Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Jun 2002
- Primary completion
- Apr 2008
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trabectedin in prostate cancer (PCa), sponsored by Massachusetts General Hospital. Primary endpoint: Number of Men With Advanced Prostate Cancer Treated With Trabectedin Who Have a PSA Response at 6 months. Started Jun 2002; status: completed.
02
Drugs
trabectedin
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00147212.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00147212.